Comparative Pharmacology
Head-to-head clinical analysis: MELFIAT 105 versus OBESTIN 30.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MELFIAT 105 versus OBESTIN 30.
MELFIAT-105 vs OBESTIN-30
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective serotonin reuptake inhibitor (SSRI); potentiates serotonergic activity in the CNS by inhibiting reuptake of serotonin at the presynaptic neuronal membrane.
ObesTin-30 is a selective serotonin reuptake inhibitor (SSRI) that blocks serotonin reuptake, increasing serotonin levels in the synaptic cleft, which modulates appetite and mood.
105 mg orally once daily in the morning.
30 mg subcutaneously once daily.
None Documented
None Documented
The terminal elimination half-life is approximately 4-6 hours, supporting twice-daily dosing in clinical practice.
Terminal elimination half-life is approximately 12 hours (range 10–14 hours) in patients with normal renal function; half-life may be prolonged to >24 hours in severe renal impairment (CrCl <30 mL/min).
Approximately 90% of an administered dose is excreted renally as unchanged drug and metabolites, with the remainder eliminated via biliary/fecal routes.
Renal excretion of unchanged drug accounts for approximately 60% of the administered dose; fecal elimination via biliary excretion accounts for approximately 30%, with the remainder as metabolites.
Category C
Category C
Anorexiant
Anorexiant